OB-GYN-L Messages for May, 2004: Re: UK Approves OTC Status For Statins

Re: UK Approves OTC Status For Statins
From: Terrence.Jones@kp.org
Thu May 13 18:07:04 2004

Messages sorted by: [ date ][ thread ][ subject ][ author ]
Next message: Richard Chudacoff, MD: "Re: tained placenta-need management advice"
Previous message: art fougner, md: "Re: tained placenta-need management advice"
Maybe in reply to: art fougner, md: "UK Approves OTC Status For Statins"
Next in thread: Anna Meenan, MD: "Re: UK Approves OTC Status For Statins"
Reply: Anna Meenan, MD: "Re: UK Approves OTC Status For Statins"
Reply: art fougner, md: "Re: UK Approves OTC Status For Statins"

This is a multipart message in MIME format. --=_alternative 007DF65788256E93_ Content-Type: text/plain; charset="iso-8859-1" Content-Transfer-Encoding: quoted-printable
Maybe a local population effect secondary to inherited (and/or acquired) diminished CYP 3A4? Try an alternate metabolic pathway (Fluvastatin/Pravastatin), or lower the dose of Lovastatin and add Zetia? Interesting presentation at SGI on statins and androgen production in PCO. (Of course, patients enrolling MUST be on effective contraception.) tj
annam@uic.edu (Anna Meenan, MD) Sent by: ob-gyn-l@obgyn.net 05/12/2004 07:28 PM Please respond to ob-gyn-l
To: Multiple recipients of list OB-GYN-L <ob-gyn-l@dns.obgyn.net> cc: Subject: Re: UK Approves OTC Status For Statins
I don't think OTC sales would matter in our small town. Statins seem to have gotten themselves a bad rep around town. It seems like everyone we put on them develops myalgias. Everyone. Of course, it's mostly small-town gossip and the power of suggestion, but it's getting to be a big problem. I've got folks with cholesterol levels over 350 who are refusing to take any meds for it and look at me like I'm trying to kill them if I even suggest it. Oh well, that's life.
Anna Meenan, MD
At Wed, 12 May 2004, art fougner, md wrote: >
>Britain to Approve
>Cholesterol Drugs
>For OTC Sale
>
>REUTERS NEWS SERVICE
>May 11, 2004; Page D5
>
>LONDON -- Statin drugs, widely taken to cut cholesterol and reduce the
>risk of heart attacks, are set to be approved for sale in Britain
>without a doctor's prescription.
>
>The move would make Britain the first country in the world to sell
>statins over the counter. Experts recommended last year that
>pharmacists should be able to supply them without a prescription
>following simple health checks carried out on the spot. An advisory
>panel to the U.S. Food and Drug Administration may consider data in
>support of allowing nonprescription sales of statins within the next
>year.
>
>"There will be an announcement on Thursday," said a spokeswoman for
>Britain's department of health, following weekend reports that Health
>Secretary John Reid was about to give a green light to over-the-counter
>sales of the drugs.
>
>Merck & Co.'s Zocor, generically called simvastatin, will be the first
>cholesterol fighter to be sold over the counter, in doses of 10
>milligrams. Zocor was once Merck's top-selling product, but it lost
>patent protection in Britain last year, and the company, based in
>Whitehouse Station, N.J., is eager to make up for lost sales by
>switching into the nonprescription market.
>
>McNeil Europe, a unit of Johnson & Johnson that specializes in European
>OTC drugs, is expected to launch Zocor Heart-Pro -- as the product will
>be known -- at the end of June or early July. It will be priced between
>£10 and £15 (about $18 to $27) per 28-day pack.
>
>The company said it was still waiting for the formal license but had
>been preparing for the launch for several months. In the U.S., a joint
>venture of Merck and Johnson & Johnson, based in New Brunswick, N.J., is
>hoping to eventually sell its Mevacor statin without a prescription.
>
>The British government has said that it would like pharmaceutical
>companies to apply for the right to sell statins without a prescription
>-- a move that could reduce the state's drug bill.
>
>Currently some 1.5 million Britons receive statin therapy and the
>National Health Service spends around £750 million on the drugs each
>year.
>
>Statins are among the most widely prescribed of all medicines, with
>Pfizer Inc.'s market leader Lipitor generating world-wide sales of $9.23
>billion in 2003.
>
>http://online.wsj.com/article/0,,SB108423039777807478,00.html?mod=health%5Fhome%5Fstories
>
>--
>art fougner, md
>ich bin ein New Yorker
>

--=_alternative 007DF65788256E93_ Content-Type: text/html; charset="iso-8859-1" Content-Transfer-Encoding: quoted-printable
 Maybe a local population effect secondary to inherited (and/or acquired) diminished CYP 3A4? Try an alternate metabolic pathway (Fluvastatin/Pravastatin), or lower the dose of Lovastatin and add Zetia? Interesting presentation at SGI on statins and androgen production in PCO. (Of course, patients enrolling MUST be on effective contraception.) tj <table width0%> <tr valign=top> <td> <td>annam@uic.edu (Anna Meenan, MD) Sent by: ob-gyn-l@obgyn.net 05/12/2004 07:28 PM Please respond to ob-gyn-l <td>                To:        Multiple recipients of list OB-GYN-L <ob-gyn-l@dns.obgyn.net>         cc:                 Subject:        Re: UK Approves OTC Status For Statins</table> I don't think OTC sales would matter in our small town.  Statins seem to have gotten themselves a bad rep around town.  It seems like everyone we put on them develops myalgias.  Everyone.  Of course, it's mostly small-town gossip and the power of suggestion, but it's getting to be a big problem.  I've got folks with cholesterol levels over 350 who are refusing to take any meds for it and look at me like I'm trying to kill them if I even suggest it.  Oh well, that's life.                     Anna Meenan, MD At Wed, 12 May 2004, art fougner, md wrote: > >Britain to Approve >Cholesterol Drugs >For OTC Sale > >REUTERS NEWS SERVICE >May 11, 2004; Page D5 > >LONDON -- Statin drugs, widely taken to cut cholesterol and reduce the >risk of heart attacks, are set to be approved for sale in Britain >without a doctor's prescription. > >The move would make Britain the first country in the world to sell >statins over the counter.  Experts recommended last year that >pharmacists should be able to supply them without a prescription >following simple health checks carried out on the spot.  An advisory >panel to the U.S.  Food and Drug Administration may consider data in >support of allowing nonprescription sales of statins within the next >year. > >"There will be an announcement on Thursday," said a spokeswoman for >Britain's department of health, following weekend reports that Health >Secretary John Reid was about to give a green light to over-the-counter >sales of the drugs. > >Merck & Co.'s Zocor, generically called simvastatin, will be the first >cholesterol fighter to be sold over the counter, in doses of 10 >milligrams.  Zocor was once Merck's top-selling product, but it lost >patent protection in Britain last year, and the company, based in >Whitehouse Station, N.J., is eager to make up for lost sales by >switching into the nonprescription market. > >McNeil Europe, a unit of Johnson & Johnson that specializes in European >OTC drugs, is expected to launch Zocor Heart-Pro -- as the product will >be known -- at the end of June or early July.  It will be priced between >£10 and £15 (about $18 to $27) per 28-day pack. > >The company said it was still waiting for the formal license but had >been preparing for the launch for several months.  In the U.S., a joint >venture of Merck and Johnson & Johnson, based in New Brunswick, N.J., is >hoping to eventually sell its Mevacor statin without a prescription. > >The British government has said that it would like pharmaceutical >companies to apply for the right to sell statins without a prescription >-- a move that could reduce the state's drug bill. > >Currently some 1.5 million Britons receive statin therapy and the >National Health Service spends around £750 million on the drugs each >year. > >Statins are among the most widely prescribed of all medicines, with >Pfizer Inc.'s market leader Lipitor generating world-wide sales of $9.23 >billion in 2003. > >http://online.wsj.com/article/0,,SB108423039777807478,00.html?mod=health%5Fhome%5Fstories > >-- >art fougner, md >ich bin ein New Yorker > 

Next message: Richard Chudacoff, MD: "Re: tained placenta-need management advice"
Previous message: art fougner, md: "Re: tained placenta-need management advice"
Maybe in reply to: art fougner, md: "UK Approves OTC Status For Statins"
Next in thread: Anna Meenan, MD: "Re: UK Approves OTC Status For Statins"
Reply: Anna Meenan, MD: "Re: UK Approves OTC Status For Statins"
Reply: art fougner, md: "Re: UK Approves OTC Status For Statins"

Return to Mail a New Message to the Forum: ob-gyn-l@obgyn.net
Forum Administrator: geffrey.klein@obgyn.net
Report Technical Problems: webmaster@obgyn.net
Last Updated: Mon Nov 2 04:55:18 2009

The American Medical Association is no longer designating CME hours for AMA Category II CME credit. However, physicians themselves may self designate learning activities as Category II CME credit hours if they feel it is of sufficient educational merit and meets the formal definitions of continuing medical education. OBGYN.net believes these interaction in this forum meets these criteria. For further information see the AMA web site.

use when must restrict search to only the ob-gyn-l forum...
Enter search keywords:
	Returns per screen: Require all keywords: